Patent Foramen Ovale
PFO Trial
The Amplatzer PFO Occluder in Patients with Recurrent Cryptogenic Stroke Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale Who Have Failed Conventional Drug Therapy
Principal Investigator
Roger J. Laham, MD
Co-Investigator
Louis Caplan, MD
Coordinator
Paula Rooney, RN
Phone: 617-632-7484
Email: prooney@bidmc.harvard.edu
Focus: Patients with patent foramen ovale (PFO)
The purpose of the Registry is to allow access to the Amplatzer PFO Occluder in subjects with a patent foramen ovale (PFO) who have already experienced at least two strokes due to presumed embolism (a blood clot blocking a brain artery) through a PFO and who have failed conventional drug therapy.
REDUCE Trial
Gore Helex™ Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients with Patent Foramen Ovale (PFO)
Principal Investigator
Roger J. Laham, MD
Co-Investigators
Louis Caplan, MD
Mary Jane McDonald, RN
Paula Rooney, RN
Cathy Troy, RN
Coordinator
Paula Rooney, RN
Phone: 617-632-7484
Email: prooney@bidmc.harvard.edu
Focus: Patients with patent foramen ovale (PFO)
The purpose of the GORE REDUCE trial is to demonstrate that antiplatelet medical management (Aspirin, Plavix , Coumadin ) plus patent foramen ovale (PFO) closure with the Gore Helex™ Septal Occluder reduces the risk of a recurrent stroke of imaging-confirmed transient ischemic attack (TIA) compared to antiplatelet medical management alone in patients with a PFO and history of stroke of imagine-confirmed TIA.
